Infection Control Program, King Hussein Cancer Center, Amman, Jordan.
Department of Cell Therapy & Applied Genomics, King Hussein Cancer Center, Amman, Jordan.
Immun Inflamm Dis. 2023 Nov;11(11):e1073. doi: 10.1002/iid3.1073.
The emergence of the COVID-19 pandemic raised questions about the interaction between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other respiratory viruses. The objective of this study is to validate the impact of the SARS-CoV-2 pandemic and its interventional measures on the respiratory viruses' transmission/infection rates.
A retrospective chart review was conducted for cancer patients who underwent laboratory-confirmed respiratory virus polymerase chain reaction (PCR) testing from January 2018 to June 2022. COVID-19 PCR tests from March 2020 to June 2022 were also included. Joinpoint regression analysis was applied to evaluate trends in respiratory virus rates. Statistical analysis was performed using Statistical Package for Social Science software.
A total of 6298 respiratory virus PCRs and 40,000 COVID-19 PCRs were performed. Data showed a significant decrease in respiratory viruses' positive cases, total respiratory tests, and respiratory viruses' activity during the pandemic period compared with the pre-pandemic period (p = .0209, .026, and .028, respectively). The joinpoint regression analysis showed a significant decrease of 13.85% in the tested positive cases of respiratory viruses between the years 2018 and 2022. Monthly, the analysis indicated a significant decrease in the positive cases by 13.46% from December 2019 to May 2021. Weekly analysis following lockdown initiation showed a reduction in respiratory virus cases.
This study provides valuable insights into the interplay between COVID-19 and other respiratory viruses, suggesting that the measures taken for COVID-19 were effective in reducing the spread of viral respiratory infections, aiding future infection control strategies to protect vulnerable populations, including cancer patients, from seasonal respiratory infections.
COVID-19 大流行的出现引发了人们对严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)与其他呼吸道病毒之间相互作用的疑问。本研究的目的是验证 COVID-19 大流行及其干预措施对呼吸道病毒传播/感染率的影响。
对 2018 年 1 月至 2022 年 6 月期间接受实验室确诊呼吸道病毒聚合酶链反应(PCR)检测的癌症患者进行了回顾性图表审查。还包括了 2020 年 3 月至 2022 年 6 月的 COVID-19 PCR 检测。采用 Joinpoint 回归分析评估呼吸道病毒率的趋势。使用社会科学统计软件包进行统计分析。
共进行了 6298 次呼吸道病毒 PCR 和 40000 次 COVID-19 PCR。数据显示,与大流行前相比,大流行期间呼吸道病毒阳性病例、总呼吸道检测和呼吸道病毒活性均显著下降(p=0.0209、0.026 和 0.028)。Joinpoint 回归分析显示,2018 年至 2022 年期间,呼吸道病毒检测阳性病例下降了 13.85%。逐月分析表明,2019 年 12 月至 2021 年 5 月,阳性病例每月下降 13.46%。锁定开始后每周进行分析,表明呼吸道病毒病例有所减少。
本研究提供了有关 COVID-19 与其他呼吸道病毒相互作用的有价值的见解,表明为 COVID-19 采取的措施有效减少了病毒性呼吸道感染的传播,有助于制定未来的感染控制策略,以保护包括癌症患者在内的弱势群体免受季节性呼吸道感染。